Advances in the Diagnosis and Treatment of Pancreatic Cancer
January 18, 2022 10:33 ET
|
Experimental Biology and Medicine
WASHINGTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 2, January, 2022) describes a novel prognostic nomogram for...
Global Cancer Stem Cells Market to Surpass $1,898.3 Million, Growing with a CAGR of 11.8% from 2019 to 2026, Post-COVID-19 Disaster by Research Dive
August 17, 2021 09:02 ET
|
Research Dive
New York, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- A newest report on the global cancer stem cells market has been added by Research Dive to its repository. The report presents exhaustive insights on...
Global Cancer Stem Cells Market to Witness Exponential Growth Owing to the Rising Efficiency of Stem Cell Therapy – Informative Report [180 Pages] by Research Dive
August 02, 2021 09:00 ET
|
Research Dive
New York, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- A recently published report by Research Dive states that the global cancer stem cells market is expected to witness a rise in revenue from $786.3...
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
November 04, 2019 01:30 ET
|
Erytech Pharma S.A.
Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass., Nov. 04, 2019 ...
ERYTECH annonce le recrutement des premiers patients dans son étude clinique de Phase 3 avec eryaspase pour le traitement en seconde ligne du cancer du pancréas
September 20, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
September 20, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...
ERYTECH publie ses résultats financiers et fait le point sur ses activités du premier semestre 2018
September 10, 2018 16:30 ET
|
Erytech Pharma S.A.
Conférence téléphonique et webcast : mardi 11 septembre à 14h30 Confirmation du virage stratégique entrepris vers le développement d’eryaspase dans les tumeurs solidesLancement de l’étude de Phase...
ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
September 10, 2018 16:30 ET
|
Erytech Pharma S.A.
Conference call and webcast scheduled for Tuesday, September 11that 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmedPhase 3 trial for eryaspase in second...
ERYTECH tiendra un webcast le 11 septembre 2018 à l’occasion de ses résultats semestriels 2018
September 06, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, 06 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant...
ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
September 06, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...